Details About Generic Salt ::  Factor

Main Medicine Class:: Antihemophilic   

Alphanine SD, Konyne 80, Profilnine SD, Proplex T, Benefix, Hemonyne, Mononine, Immunine VH
Class: Antihemophilic

 

Drugs Class ::

 Action Restores hemostasis in patients with Factor IX deficiency.

Indications for Drugs ::

 Indications Management of Factor IX deficiency (hemophilia B, Christmas disease), bleeding episodes in patients with inhibitors to Factor VIII; reversal of coumarin anticoagulant hemorrhage; prevention or control of bleeding in patients with Factor VII deficiency (Proplex T only).

Drug Dose ::

 Route/Dosage

ADULTS & CHILDREN: IV Dose based on patient condition, degree of deficiency and desired level of Factor IX to be achieved. Dosing guideline: 1 U/kg × body weight (kg) × desired increase (% of normal) Factor VII deficiency: 0.5 U/kg × body weight (kg) × desired increase (% of normal), repeated q 4 to 6 h prn.

Hemarthroses

In hemophiliacs with inhibitors to Factor VIII, IV 75 IU/kg. Maintenance: Usually, IV 10 to 20 IU/kg/day. Hemophilia A patients with inhibitors to Factor VIII: IV 75 IU/kg as single dose followed by second dose in 12 hr if necessary.

Prophylaxis

In patients with hemophilia B, IV 10 to 20 IU/kg 1 to 2 times/wk.

Contraindication ::

 Contraindications Treatment of Factor VII deficiency (except for Proplex T); liver disease with signs of intravascular coagulation or fibrinolysis.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Hepatitis and HIV infection: Some risk due to preparation from pooled units of plasma. Intravascular coagulation: If signs of DIC occur, stop infusion promptly.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CV: Thrombosis or DIC; changes in BP; MI (with high doses). CNS: Headache. Nausea; vomiting. DERM: Flushing; urticaria. RESP: Pulmonary embolism. OTHER: Pyrogenic reactions (eg, fever and chills); tingling.

Drug Mode of Action ::  

 Action Restores hemostasis in patients with Factor IX deficiency.

Drug Interactions ::

 Interactions

Aminocaproic acid: May increase risk of thrombosis.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note hepatitis B vaccination.
  • In patients with major bleeding or those being prepared for surgery, monitor Factor VII or IX assays daily prior to infusion.
  • In patients receiving Factor IX for prolonged periods, monitor Factors II, IX and X daily.
  • Assess BP and heart rate prior to and during infusion.
  • Observe for signs of DIC, MI, pulmonary embolus and venous thrombosis.
  • Monitor I&O and observe for hemolytic reaction.
  • Stop infusion and notify physician if any of the following develops: tingling, urticaria, chills, fever, headache, flushing, nausea or vomiting, change in heart rate or BP. Infusion may be restarted at a slower rate when symptoms subside.
  • Discontinue infusion if signs of DIC (eg, petechiae, oozing from puncture sites), tachycardia, tachypnea, or joint pain develop, and notify physician.

Drug Storage/Management ::

 Administration/Storage

  • Use powder and diluent at room temperature when reconstituting.
  • Gently swirl solution during reconstitution to prevent foaming. Infuse within 3 hr of reconstitution.
  • Administer by IV infusion only.
  • Start infusion within 3 hr after reconstitution.
  • Maintain prescribed rate of infusion, (eg, Konyne-80, 100 U/min; Profilnine SD, < 10 ml/min; Proplex T, < 3 ml/min.)
  • Store powdered form of drug in refrigerator. Do not freeze.
  • Do not refrigerate reconstituted solution.

Drug Notes ::

 Patient/Family Education

  • Instruct patient to report any chills, headache, urticaria, tingling, flushing, or nausea and vomiting to nurse or physician.
  • Tell patient to immediately report any chest pain/pressure or difficulty breathing.
  • Caution patient to avoid activities that could lead to injury or bleeding.
  • Instruct patient to report any signs of bleeding (eg, petechiae, purpura, bleeding gums or rectum, blood in urine).
  • Discuss questions concerning HIV and hepatitis risk.
  • Instruct patient to report any signs or symptoms of AIDS or hepatitis.
  • Review methods of preventing and stopping bleeding.
  • Advise patient to carry identification/information regarding bleeding tendency.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.